A phase 3B randomized, double-blind, double-dummy, active controlled multi-center study assessing the efficacy and safety of Abrocitinib compared with Dupilumab in adult participants on background topical therapy with moderate to severe atopic dermatitis.

Register Today!.

Trial Information

Start DateSummer 2020
End DateTBD
Trial Duration30 weeks with the option of long-term extension
Number of Visits12
Lead CRCSuzanne Fleming
StatusOngoing

For additional information
on this trial contact:

Phone705-566-0005